✦ LIBER ✦

Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission

✍ Scribed by Dr. Peter H. Wiernik; Janice P. Dutcher; Mary Todd; Geralyn Caliendo; Laura Benson

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 411 KB
Volume: 47
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830470109

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low dose interleukin-2 following intensi

Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission

✍ Richard M. Stone; Daniel J. DeAngelo; Anna Janosova; Ilene Galinsky; Christine C 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 343 KB 👁 2 views

## Abstract The most important problem in the therapy of patients with acute myeloid leukemia (AML) is relapse after intensive therapy. We sought to determine if interleukin‐2 (low‐dose with intermittent boluses) administration could be feasibly administered after standard therapy to potentiate ant

A pilot study of interleukin-2 for adult

A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

✍ Jorge E. Cortes; Hagop M. Kantarjian; Susan O'Brien; Francis Giles; Michael J. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## BACKGROUND. Interleukin-2 (IL-2) has immunomodulatory effects, including stimulating the activity of cytotoxic T cells and natural killer cells, and inducing the generation of lymphokine-activated killer cells. The authors investigated whether IL-2 may improve the duration of complete remission